Sicilia
Copyright policy )Sicilia
In Sicily region 39,6% of women (aged 25-64) are screened regularly, meaning every 3 years. Considering regional tariffs and vaccine acquisition cost, the vaccination of 12-year-old girls with a 90% coverage could prevent 169 cases of cervicocarcinoma and 68 related deaths and thus results to be cost-effective (15.534 €/QALY). When the vaccination programme is extended to 16-year-old girls a further 181 cancer cases and 75 deaths could be prevented, with a very similar cost-effectiveness ratio. In Sicily region, the net cost for woman vaccinated is 171 € for the single cohort and 176 € for the multiple cohort.
- GlaxoSmithKline (Belgium) Belgium
- National Institute for Nuclear Physics Italy
- University of Pavia Italy
- Università Luigi Bocconi Italy
- GlaxoSmithKline (Italy) Italy
Medicine (General), R5-920, economic & clinical impact, Pharmacoeconomics; Health economics, hpv vaccination, Sicily; HPV vaccination; Economic & clinical impact, sicily, General Medicine
Medicine (General), R5-920, economic & clinical impact, Pharmacoeconomics; Health economics, hpv vaccination, Sicily; HPV vaccination; Economic & clinical impact, sicily, General Medicine
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!